9:38 AM
 | 
Sep 21, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Innovent's PD-1 inhibitor leads to 68.4% ORR in Phase Ib for first-line NSCLC

Innovent Biologics Inc. (Suzhou, China) reported data from 19 evaluable patients with non-squamous non-small cell lung cancer (NSCLC) in cohort D of a Chinese Phase Ib trial showing that anti-PD-1 antibody sintilimab (IBI308) plus Alimta pemetrexed and cisplatin as first-line treatment led to an objective response rate (ORR) of 68.4%. Median duration of response, progression-free survival (PFS) and overall...

Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >